Skip to main content

Table 1 Baseline characteristics of patients

From: A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis

 

Total

Patients starting with animated exercise program (Wii console)a1

Patients starting with conventional home-based physical exercisesa1

Number of patients, n

30

15

15

Age (years), mean (SD)

56 (±9)

52 (±8)

59 (±9)

Age (years), min.

34

34

45

Age (years), max.

69

65

69

Age > 60 years, n (%)

11 (37 %)

3 (20 %)

8 (53 %)

Age 50 – 60 years, n (%)

10 (33 %)

7 (47 %)

3 (20 %)

Age <50 years, n (%)

9 (30 %)

5 (33 %)

4 (27 %)

Female, n (%)

25 (83 %)

10 (67 %)

15 (100 %)

Disease duration (years), mean (SD)

13 (±9)

10 (±7)

16 (±9)

disease duration (years), max.

36

26

36

disease duration (years), min.

1

1

1

DAS28, mean (SD)

2.8 (±1.2)

3.0 (±1.5)

2.6 (±0.9)

DAS28 score, max.

5.3

5.3

4.4

DAS28 score, min.

0.5

0.9

0.5

HAQ-DI score, mean (SD)

0.85 (±0.53)

0.72 (±0.52)

0.98 (±0.51)

HAQ-DI score, max.

1.75

1.75

1.63

HAQ-DI score, min.

0.00

0.00

0.00

Patient’s VAS disease activity, mm

17

16

18

Current biological DMARD therapy

 Rituximab, n (%)

12 (40 %)

7 (47 %)

5 (33 %)

 Tocilizumab, n (%)

10 (33 %)

5 (33 %)

5 (33 %)

 Abatacept, n (%)

5 (17 %)

2 (13 %)

3 (20 %)

 Etanercept, n (%)

2 (6 %)

1 (7 %)

1 (7 %)

 Certolizumab, n (%)

1 (3 %)

0 (0 %)

1 (7 %)

Previous biological DMARD therapy

 Rituximab, n (%)

4 (13 %)

2 (13 %)

2 (13 %)

 Tocilizumab, n (%)

3 (10 %)

1 (7 %)

2 (13 %)

 Abatacept, n (%)

2 (6 %)

1 (7 %)

1 (7 %)

 Etanercept, n (%)

10 (33 %)

7 (47 %)

3 (20 %)

 Certolizumab, n (%)

1 (3 %)

1 (7 %)

0 (0 %)

 Golimumab, n (%)

1 (3 %)

0 (0 %)

1 (7 %)

 Secukinumab, n (%)

1 (3 %)

1 (7 %)

0 (0 %)

 Infliximab, n (%)

6 (20 %)

2 (13 %)

4 (27 %)

 Anakinra, n (%)

1 (3 %)

1 (7 %)

0 (0 %)

  ≥ 3 previous biological DMARD’s, n

7 (23 %)

4 (27 %)

3 (20 %)

  ≥ 2 previous biological DMARD’s, n

8 (27 %)

4 (27 %)

4 (27 %)

 only 1 previous biological DMARD, n

6 (20 %)

2 (13 %)

4 (27 %)

  1. a1 with a cross-over to the other treatment arm after 12 weeks SD, standard deviation; min, minimum; max, maximum; HAQ-DI, health assessment questionnaire disability index; DAS28, disease activity score using the 28 joint count; DMARD, disease modifying anti-rheumatic drug; VAS, Visual analogue scale